Recent 8-K filings for KPRX
Highest-materiality recent filing
Kiora Pharmaceuticals announces 1-for-9 reverse stock split effective June 11, 2024 to meet Nasdaq bid price requirement
- 1-for-9 reverse stock split filed June 6, 2024; effective at open of market on June 11, 2024.
- Outstanding shares will reduce from ~26.7M to ~2.97M; fully diluted from ~100.1M to ~11.1M.
-
Kiora Q1 cash $13.9M, $5.0M equity raise post-quarter; KIO-301 enrollment nearly 50% in Phase 2
Q1 cash $13.9M; post-quarter raised $5.0M in equity from Perceptive Advisors; operational runway into late 2028.
-
Kiora Pharmaceuticals closes $5M private placement with Perceptive Advisors; warrants could add $19M
Closed private placement raising $5.0M upfront; potential $19M from warrant exercise.
-
Kiora Pharmaceuticals CDO Eric Daniels to resign April 17; successor search initiated
Eric J. Daniels resigns as Chief Development Officer effective April 17, 2026, to pursue other opportunities.
-
Kiora Pharmaceuticals reports FY2025 net loss of $10.8M; two Phase 2 trials underway
Net loss of $10.8M for 2025 vs net income of $3.6M in 2024 due to $16M upfront payment from Théa in prior year.
-
Kiora reports Q3 net income of $27K; cash runway into late 2027; two Phase 2 trials enrolling
Cash, equivalents and investments $19.4M; collaboration receivables $1.2M; tax receivables $1.5M.
-
Kiora Pharmaceuticals furnishes updated investor presentation for H.C. Wainwright conference
Filed 8-K on August 13, 2025 to disclose updated investor presentation (Exhibit 99.1).
-
Kiora Q2 net loss $2.2M; initiated two Phase 2 retinal trials, Senju deal up to $110M
Net loss of $2.2M in Q2 2025, flat YoY; cash and equivalents $20.7M, runway into late 2027.
-
Kiora shareholders elect directors, approve say-on-pay and auditor at annual meeting
Carmine Stengone and Brian M. Strem elected as Class I directors for three-year term.
-
Immediate $1.25M option payment; if exercised, mid-single-digit million upfront and up to $110M in development, regulatory, and commercial milestones.
-
Kiora Q1 net loss $2.2M; cash $24.1M into late 2027; initiates two Phase 2 trials
Net loss $2.2M vs net income $13.4M in Q1 2024 due to $16M upfront from Théa in prior year.
-
Kiora reports 2024 net income $3.6M; two Phase 2 retinal trials approved; cash runway into 2027
Year-end cash, equivalents, and short-term investments $26.8M; expected runway into 2027.
-
Kiora formalizes employment agreements with CFO and CDO; base salaries $337K and $443K
Eric Daniels (CDO) receives $443,000 annual base salary, 40% bonus target, and $6,500/month relocation gross-up for 15 months.
-
Kiora Q3 net loss $3.4M; cash $29M; advancing two Phase 2 retinal trials
Cash and equivalents $29.0M at Sept 30, plus $1.8M collaboration receivables; runway into 2027.
-
Kiora receives IND approval for Phase 2 trial of KIO-301 in retinitis pigmentosa
ABACUS-2 is a 36-patient, multi-center, double-masked, randomized, controlled Phase 2 trial.
-
Kiora reports Q2 net loss $2.2M, cash $27.8M; advancing two Phase 2 retinal trials
Q2 revenue $20K (grant); net R&D expense $0.9M after $1.1M TOI reimbursement credits.
-
Kiora Pharma receives EU orphan designation for KIO-301 in inherited retinal dystrophies
EMA grants Orphan Medicinal Product Designation for KIO-301 in non-syndromic rod-dominant retinal dystrophies including retinitis pigmentosa.
-
Kiora appoints Walters-Hoffert to board, promotes Tosca to CFO, regains Nasdaq compliance
Lisa Walters-Hoffert appointed independent director and audit committee chair; Kenneth Gayron resigned.
-
1-for-9 reverse stock split filed June 6, 2024; effective at open of market on June 11, 2024.
-
Kiora Pharma Q1 net income $13.5M on $16M TOI revenue; $31.3M cash; KIO-301 Phase 2 on track
Ended Q1 with $31.3M cash plus $1.8M R&D tax credits; runway over 2 years.
-
Kiora shareholders approve reverse stock split and increase authorized shares to 150M
Reverse stock split of common stock approved at a ratio between 1-for-2 and 1-for-10; board will set exact ratio and timing.
-
Kiora reports 2023 net loss $12.5M; cash >$30M post partnership and placement
Net loss $12.5M in 2023 vs $13.6M in 2022; R&D expense $4.0M, G&A $4.7M.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.75 · Median 0.65 · Most common event earnings